key: cord-0782256-npjt8u7c
authors: Hemsath, Jack R.; Liaci, A. Manuel; Rubin, Jeffrey D.; Parrett, Brian J.; Lu, Shao-Chia; Nguyen, Tien V.; Turner, Mallory A.; Chen, Christopher Y.; Cupelli, Karolina; Reddy, Vijay S.; Stehle, Thilo; Liszewski, M. Kathryn; Atkinson, John P.; Barry, Michael A.
title: Ex Vivo and In Vivo CD46 Receptor Utilization by Species D Human Adenovirus Serotype 26 (HAdV26)
date: 2021-09-30
journal: bioRxiv
DOI: 10.1101/2021.09.28.462271
sha: 08a6969f0ee7b10eeec44a4ac5c3021cb87fc43d
doc_id: 782256
cord_uid: npjt8u7c

Human adenovirus serotype 26 (Ad26) is used as a gene-based vaccine against SARS-CoV-2 and HIV-1. Yet, its primary receptor portfolio remains controversial, potentially including sialic acid, CAR, integrins, and CD46. We and others have shown that Ad26 can use CD46, but these observations were questioned by the inability to co-crystallize Ad26 fiber with CD46. Recent work demonstrated that Ad26 binds CD46 with its hexon protein rather than its fiber. We examined the functional consequences of Ad26 for infection in vitro and in vivo. Ectopic expression of human CD46 on Chinese hamster ovary cells increased Ad26 infection significantly. Deletion of the complement control protein domains CCP1 or CCP2 or the serine-threonine-proline (STP) region of CD46 reduced infection. Comparing wild type and sialic acid-deficient CHO cells, we show that the usage of CD46 is independent of its sialylation status. Ad26 transduction was increased in CD46 transgenic mice after intramuscular (IM) injection, but not after intranasal (IN) administration. Ad26 transduction was 10-fold lower than Ad5 after intratumoral (IT) injection of CD46-expressing tumors. Ad26 transduction of liver was 1000-fold lower than Ad5 after intravenous (IV) injection. These data demonstrate the use of CD46 by Ad26 under certain situations, but also show that the receptor has little consequence by other routes of administration. Finally, IV injection of high doses of Ad26 into CD46 mice induced release of liver enzymes in the bloodstream and reduced white blood cell counts, but did not induce thrombocytopenia. This suggests that Ad26 virions do not induce direct clotting side effects seen during COVID-19 vaccination with this serotype of adenovirus. IMPORTANCE Human species D Ad26 is being pursued as a low seroprevalence vector for oncolytic virotherapy and gene-based vaccination against HIV-1 and SARS-CoV-2. However, there is debate in the literature about its tropism and receptor utilization, which directly influence its efficiency for certain applications. This work was aimed at determining which receptor(s) this virus uses for infection, and its role in virus biology, vaccine efficacy, and importantly, in vaccine safety.

intratumoral (IT) injection of CD46-expressing tumors. Ad26 transduction of liver was 48 1000-fold lower than Ad5 after intravenous (IV) injection. These data demonstrate the 49 use of CD46 by Ad26 under certain situations, but also show that the receptor has little 50 consequence by other routes of administration. Finally, IV injection of high doses of 51

Ad26 into CD46 mice induced release of liver enzymes in the bloodstream and reduced 52 white blood cell counts, but did not induce thrombocytopenia. This suggests that Ad26 53 virions do not induce direct clotting side effects seen during COVID-19 vaccination with 54 this serotype of adenovirus. 55

Human species D Ad26 is being pursued as a low seroprevalence vector for oncolytic 58 virotherapy and gene-based vaccination against HIV-1 and SARS-CoV-2. However, 59 there is debate in the literature about its tropism and receptor utilization, which directly 60 influence its efficiency for certain applications. This work was aimed at determining 61 which receptor(s) this virus uses for infection, and its role in virus biology, vaccine 62 efficacy, and importantly, in vaccine safety. 63

This work compares the in vivo activity of Ad26 with benchmark Ad5 virus in mice with 176 and without CD46. Finally, given recent concerns with thrombotic thrombocytopenia in 177 people vaccinated with Ad26 and ChAdOx1 (48, 49) , this study also examined if 178 intravenous delivery of high doses of Ad26 into CD46 transgenic mice can provoke 179 changes in blood counts, platelets, and blood chemistry. were generously provided by Dr. Kah-Whye Peng (Mayo Clinic) These were cut with BglII and ApaI and cloned into pHook2-PSTCD (50) in frame and 202 between the alpha1-antitrypsin secretory leader and the PDGFR transmembrane 203 domain from pHook2 (Invitrogen) that allows cell surface display of fusion proteins. 204 CHO and Lec2 stable cell lines were selected with G418 as above. Stable cells were 205 stained with MEM-258 CD46 antibody and verified on a flow cytometer for CD46 206 expression before use (Supplemental Figure S1 ). B16 mouse melanoma cells were 207 purchased from ATCC. These cells were first modified with pCDNA3-CAR expressing 208 human CAR by transient transfection and selection with G418. B16 cells were also 209 transduced with a lentivirus expressing human CD46 followed by selection in 210 puromycin. CAR and CD46 expression in the resulting B16-CAR-CD46 cells was 211 verified by flow cytometry. 212

Adenoviruses. Replication-defective Ad5 (RD-Ad5) and replication-competent Ad5 213 (RD-Ad5) expressing the green fluorescent protein-luciferase (GFP-Luc) fusion protein 214 were produced as described in (51). RD-Ad6, RD-Ad26 and RC-Ad26 expressing GFP-215

Luc were generated as in (52). RD-Ad5, RD-Ad6 and RC-Ad26 were grown in 293 cells. 216

The Ad5 E1 in 293 cells supports E1 deleted species C viruses, but not other Ads 217 species viruses (53). Therefore, E1-deleted RD-Ad26 was grown in 293-IX-E4 cells that 218 also provide Ad5 E4 proteins as in (43). All viruses were purified by double CsCl 219 banding and viral particle (vp) concentrations were calculated from OD260. Cryo-Electron Microscopy of Ad26. We recently described the first structure of 230 species D Ad26 by cryo-electron microscopy (cryo-EM) at 3.7Å resolution and details of 231 these analyses can be found in (26). Figure 1A shows the radially color-coded Ad26 CBCs and Blood Chemistry. C57BL/6-CD46 transgenic mice were injected with 10 11 254 vp of RC-Ad26. After 24 hours, blood was collected via submandibular vein puncture 255 and collected in BD lithium heparin and K 2 EDTA tubes. Complete blood cell counts 256 (CBCs) and blood chemistry were analyzed on VetScan HM5 and Piccalo Express 257 instruments, respectively. Controls were completed following the same procedure 258 except no virus was administered prior. These analyses were performed by Mayo 259

Pharmacology and Toxicology Core. 260 Statistical Analyses. All analyses were performed using GraphPad Prism. 261

Ad26 Infection via CD46 on Cells. New data demonstrates that Ad26 interacts with 263 CD46 via its hexon protein rather than by its fiber protein (47). Yet the question remains 264 as to how the virus might use and balance interactions with CD46, integrins or sialic 265 acid in natural and therapeutic settings. To examine this further, replication-defective 266

Ad26 (RD-Ad26) expressing GFP-Luciferase was incubated with Chinese hamster 267 ovary (CHO) cells that naturally lack both CAR and CD46. This infection was compared 268

to CHO-CD46-C1 cells that express the C1 variant of human CD46 that includes only 269 the single C STP domain (54) and to CHO cells expressing human CAR and human 270

Junctional Adhesion Molecule 1 (JAM1) (Fig. 3) . In the absence of any added human 271 receptors, Ad26 infected CHO cells at significant levels (p < 0.0001 by one-way 272

RGD loop or by sialic acid interactions. Adding CAR or JAM1 did not increase this 274 transduction over unmodified CHO cells. In contrast, Ad26 infected CHO-CD46-C1 cells 275 6 to 7-fold higher than all of the other cell lines (p < 0.0001). These data suggest that 276 infection was significantly lower on CD46-BC1-CCP1 or CCP2 (Fig. 4) . Infection was 282 also lower on CD46-BC1-STP cells (p < 0.001). These data suggest that Ad26 binds to 283

CCPs 1 and 2 of CD46 and that the presence of an STP domain also influences this 284 interaction.

previously showed that a combination of CD46 antibody and cyclic RGD peptide can 287 almost completely inhibit Ad26 infection of primary human B cells (7). In contrast, 288 treating cells with neuraminidase or with wheat germ agglutinin to block sialic acid 289 interactions did not inhibit Ad26 in our hands (7). This suggested that Ad26 uses CD46 290 and integrins, but not sialic acid, at least on these cells. In contrast, recent studies 291

showed that Ad26 knob binds sialic acid at the same binding site as Ad37 (46). 292

Since the CCP1-2 and STP domains of CD46 are all heavily glycosylated, we 293 hypothesized that Ad26 might not use CD46 as a protein receptor, but might instead 294 use the protein as a scaffold that displays sialic acid ( Fig. 2 and (33) ). In this model, 295 over-expression of CD46 might simply increase the raw amount of sialic acid on the cell 296 surface. Alternately, the extended "hockey stick" structure of CD46 (32) might simply 297 provide an easily accessible landing pad to bind sialic acid on cells. 298

To test this, we expressed several versions of CD46-BC1 on either sialylation-299 competent CHO cells or sialylation-deficient LEC2 cells. LEC2 cells are CHO cell 300 mutants that have a 90% reduction in sialylation of cellular glycoproteins due to an 301 inability to translocate CMP-sialic acid across Golgi vesicle membranes, and thus result 302 in different glycosylation patterns (Fig. 5A, right panel) When Ad5 and Ad26 were used to infect CHO cells expressing these proteins, Ad26 312 overall mediated significantly stronger gene delivery than CAR-utilizing Ad5, irrespective 313 of whether CD46 was present or not (Fig. 5B) . However, Ad26 once again infected 314 CHO cells expressing wild type CD46-BC1 cells more efficiently than unmodified CHO 315 cells (p < 0.0001). Interestingly, Ad26 infection of the STP-PDGF and Ecto-PDGF 316 chimeras was no better than the transduction of unmodified CHO cells. 317

The same CD46 plasmids were used to modify LEC2 cells (57). Indeed, Ad26 318 transduction of unmodified LEC2 cells resulted in more than 50% decreased luciferase 319 levels compared to CHO cellsas was the case for LEC2 cells expressing Ecto-PDGF 320 and STP-PDGF, which again yielded no discernable effect. However, when LEC2 cells 321 overexpressing wild type CD46-BC1 were infected with Ad26, the level of luciferase 322 gene expression was virtually identical to that observed on CHO-CD46-BC1 cells (Fig.  323   5B) . These results suggested that Ad26 does use sialic acid for some level of infection, 324 perhaps on other cellular proteins, but that CD46 can functionally substitute sialic acid 325 when expressed at high levels, irrespective of its sialylation status. Ad26 clearly does 326 not use CD46 as a mere scaffold for carbohydrate binding, and surprisingly, its 327 transmembrane and cytoplasmic domains seem to be relevant for Ad26 transduction as 328

well. Ad5 infection interestingly increased on all of the LEC2 cells.

on nearly all human cells (28). In contrast, normal mice express CD46 only in the testes 331 and retina (39-41). We previously showed that in vivo intramuscular (IM) injection of 332 RD-Ad26 into C57BL/6-CD46 transgenic mice mediated significantly stronger 333 transduction than similar injections in normal BALB/c mice (43). While this supports the 334 use of CD46 by the virus in vivo, this was not a direct comparison of Ad26 in mice with 335 and without CD46. 336

To examine this more directly with viruses that are relevant to oncolytic virotherapy, 337

replication-competent Ad5 (RC-Ad5) and replication-competent Ad26 (RC-Ad26) 338 expressing GFP-Luciferase were compared in vivo in C57BL/6 or C57BL/6-CD46 339 transgenic mice (60) (Figure 6) . These C57BL/6-CD46 transgenic mice contain a 340 knock-in of the human CD46 gene as well as locus control regions from human 341 chromosome 1, granting these mice near-ubiquitous expression of the human CD46 342 protein with expression patterns dictated by the human promoter sequence (56). To 343 control for heterogeneity of mouse genetic backgrounds skewing transduction, the 344 C57BL/6 mice used for these experiments were CD46littermates of the CD46 + mice 345 used. 346 1x10 10 virus particles (vp) of RC-Ad5-GL or RC-Ad26-GL were injected intramuscularly 347 (IM), intranasally (IN), intravenously (IV), or intratumorally (IT) into groups of 5 mice and 348 luciferase imaging was performed 2 days later (Fig. 6) . Ad26 mediated 15-fold higher 349 transduction in CD46 + mice than CD46mice by the IM route (p < 0.0001 by one-way 350 ANOVA, Fig. 6A ). Ad26 transduction was also 2-fold higher than Ad5 transduction in the muscle of CD46 + mice. In contrast, Ad5 and Ad26 transduction was nearly equal in 352 mice with and without CD46 when delivered intranasally. Overall, transduction by both 353 vectors decreased approximately 10-fold by the IN route when compared to the IM 354 route. We therefore conclude that the usage of CD46 by Ad26 in vivo is dependent on 355 the administered route, and that there seems to be preferred usage of CD46 following 356 IM administration. 357 RC-Ad5-GL and RC-Ad26-GL were next injected into B16-CAR-CD46 subcutaneous 358 tumors in CD46 transgenic mice and luciferase expression was measured ( Fig. 6B and 359 C). After intravenous administration, Ad5 mediated more than 100-fold higher luciferase 360 expression in the liver than Ad26 (Fig. 6B) . When the two vectors were injected IT into 361 the B16-CAR-CD46 tumors, Ad5 mediated up to 10-fold higher tumor infection than 362 Ad26 (Fig. 6C) We previously examined in detail the ability of Ad5 to provoke clotting side effects after 373 intravenous injection (61). An IV dose of 10 11 vp of Ad5 induces significant 374 thrombocytopenia within 24 hours. This response is rapid as demonstrated by increases 375 in d-dimer fibrin degradation products in the blood within 6 hours of injection. Ad5 376 appears to induce this effect by binding and activating platelets and endothelial cells 377

directly (61). 378

To examine if leak of Ad26 into the blood might also perturb the clotting system, a 379 similar large 10 11 vp dose of RC-Ad26 was administered IV to CD46 transgenic mice 380 and complete blood counts (CBC) and blood chemistry analyses were performed one 381 day later (Fig. 7) . In contrast to Ad5, the IV bolus of Ad26 failed to provoke notable 382 changes in platelets when compared to control animals (Fig. 8A) . 383

In contrast, Ad26 did induce significant reductions in white blood cells, lymphocytes, 384 and monocytes (p < 0.001, Fig. 8B, C, and D) after IV injection. Ad26 also produced 385 significant elevations in liver enzymes including alanine transaminase (ALT) and 386 aspartate aminotransferase (AST) after IV injection (p < 0.01, Fig. 8E and F) . (62)These 387 data suggest that direct exposure of blood proteins and cells does not provoke 388 thrombocytopenia but does cause reductions in certain nucleated white blood cells and 389 liver damage. 390

Our previous work found that species D human Ads can be potent oncolytic viruses 393 against B cell cancers (6, 7) and have utility as mucosal gene-based vaccines (9, 43) . 394

Receptor utilization testing on primary patient B cell cancer cells showed that Ad26 uses 395 CD46 and integrin binding to infect these cells (7). Blocking CD46 antibodies reduced 396

Ad26 infection in these B cells, but this inhibition was not 100%. Combined blockade of 397 CD46 and integrin could inhibit infection nearly 100% (7). Removing or blocking sialic 398 acid on B cells had no effect. 399

More recent work reported that Ad26 knob does not bind CD46 and instead uses v3 400 integrin as its primary receptor on epithelial cells (44). Other work showed that Ad26 401 knob could bind CAR, but could not bind CD46 (45). showing as we did that Ad26 does indeed use CD46, but not with its fiber, but rather 406 with its hexon (47). 407

We proceeded to functional testing on more controlled target cells than the primary B 408 cell cancer cells used in our previous studies, and to permutate CD46 constructs that 409 lack specific parts of the protein. Ad26 testing on well-defined CHO-CD46 cell lines (28, 410 29, 33) Schematic of CD46 glycosylation in CHO and LEC2 sialylation-deficient cells. B) The 699 indicated cells were incubated with Ad26-GL and luciferase activity was measured 2 700 days later. * p < 0.05, **** p < 0.0001. 701 Figure 6 . In Vivo Luciferase Activity After Intramuscular, Intranasal, Intravenous, 702 and Intratumoral Administration of Ad5 or Ad26 in CD46and CD46 + Mice. A) 703

Luciferase imaging 2 days after intranasal or intramuscular injection of 1x10 10 vp of RC-704

Ad5-GL or RC-Ad26-GL. B) Luciferase activity in livers 2 days after intravenous 705 injection of 3x10 10 vp of RC-Ad5-GL or RC-Ad26-GL into CD46 transgenic mice C) 706

Luciferase activity in tumors 2 days after intratumoral injection of 3x10 10 vp of RC-Ad5-707 GL or RC-Ad26-GL into B16-CAR-CD46 subcutaneous tumors. Graphs show the same 708 data on a log scale on the left and a linear scale on the right. * p < 0.05, **** p < 0.0001. 709 Aspartate aminotransferase (AST). ** p < 0.01, *** p < 0.001 by T test.

Genetic content and evolution of 461 adenoviruses

Regulation of CD46 RNA Alternative Splicing

Complement regulatory protein CD46 596 protects against choroidal neovascularization in mice

Characterization of human 598 membrane cofactor protein (MCP; CD46) on spermatozoa

Membrane cofactor protein (MCP; CD46) expression in 602 transgenic mice

The evolution of mouse and human 604 complement C3-binding proteins: divergence of form but conservation of 605 function

Measles virus infection in a transgenic 608 model: virus-induced immunosuppression and central nervous system disease

The Complement Regulatory Protein CD46 Deficient Mouse 612

Spontaneously Develops Dry-Type Age-Related Macular Degeneration-Like 613

CD46-mediated 615 transduction of a species D adenovirus vaccine improves mucosal vaccine 616 efficacy

alphavbeta3 Integrin Is Required for Efficient Infection of Epithelial Cells with 619

Human Adenovirus Type 26

Diversity within the adenovirus fiber knob 622 hypervariable loops influences primary receptor interactions

Human species 629

D adenovirus hexon capsid protein mediates cell entry through a direct 630 interaction with CD46

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

Thrombotic 635 Thrombocytopenia after Ad26.COV2.S Vaccination

Metabolic biotinylation of secreted and cell surface 638 proteins from mammalian cells

Generation of a Kupffer Cell-evading Adenovirus for Systemic 641 and Liver-directed Gene Transfer

Protection against 643 divergent influenza H1N1 virus by a centralized influenza hemagglutinin

Novel replication-incompetent adenoviral B-group vectors: 649 high vector stability and yield in PER.C6 cells

Antibody-targeted cell fusion

Protection of mammalian cells from complement-mediated 655

lysis by transfection of human membrane cofactor protein and decay-656 accelerating factor

Membrane 658 cofactor protein (CD46) protects cells from complement-mediated attack by an 659 intrinsic mechanism

Complementation between mutants of CHO cells 661 resistant to a variety of plant lectins

Translocation across Golgi vesicle membranes: a CHO glycosylation mutant 664 deficient in CMP-sialic acid transport

CD46 is 666 phosphorylated at tyrosine 354 upon infection of epithelial cells by Neisseria 667 gonorrhoeae

Measles virus spread and pathogenesis in 670 genetically modified mice

Polyethylene 672 glycol modification of adenovirus reduces platelet activation, endothelial cell 673 activation, and thrombocytopenia

Mining the adenovirus 675 virome for oncolytics against multiple solid tumor types

 Goudsmit J, Barouch DH. 2008. 473 Immune control of an SIV challenge by a T-cell-based vaccine in rhesus 474 monkeys.